Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15

1.

Multiple myeloma exploits Jagged1 and Jagged2 to promote intrinsic and bone marrow-dependent drug resistance.

Colombo M, Garavelli S, Mazzola M, Platonova N, Giannandrea D, Colella R, Apicella L, Lancellotti M, Lesma E, Ancona S, Palano MT, Barbieri M, Taiana E, Lazzari E, Basile A, Turrini M, Pistocchi A, Neri A, Chiaramonte R.

Haematologica. 2019 Oct 3. pii: haematol.2019.221077. doi: 10.3324/haematol.2019.221077. [Epub ahead of print]

2.

Long non-coding RNA NEAT1 targeting impairs the DNA repair machinery and triggers anti-tumor activity in multiple myeloma.

Taiana E, Favasuli V, Ronchetti D, Todoerti K, Pelizzoni F, Manzoni M, Barbieri M, Fabris S, Silvestris I, Gallo Cantafio ME, Platonova N, Zuccalà V, Maltese L, Soncini D, Ruberti S, Cea M, Chiaramonte R, Amodio N, Tassone P, Agnelli L, Neri A.

Leukemia. 2019 Aug 19. doi: 10.1038/s41375-019-0542-5. [Epub ahead of print]

PMID:
31427718
3.

Expanding the repertoire of miRNAs and miRNA-offset RNAs expressed in multiple myeloma by small RNA deep sequencing.

Agnelli L, Bisognin A, Todoerti K, Manzoni M, Taiana E, Galletti S, Cutrona G, Gaffo E, Bortoluzzi S, Neri A.

Blood Cancer J. 2019 Feb 19;9(3):21. doi: 10.1038/s41408-019-0184-x.

4.

Long non-coding RNA NEAT1 shows high expression unrelated to molecular features and clinical outcome in multiple myeloma.

Taiana E, Ronchetti D, Favasuli V, Todoerti K, Manzoni M, Amodio N, Tassone P, Agnelli L, Neri A.

Haematologica. 2019 Feb;104(2):e72-e76. doi: 10.3324/haematol.2018.201301. Epub 2018 Sep 13. No abstract available.

5.

A compendium of long non-coding RNAs transcriptional fingerprint in multiple myeloma.

Ronchetti D, Agnelli L, Pietrelli A, Todoerti K, Manzoni M, Taiana E, Neri A.

Sci Rep. 2018 Apr 26;8(1):6557. doi: 10.1038/s41598-018-24701-8.

6.

Drugging the lncRNA MALAT1 via LNA gapmeR ASO inhibits gene expression of proteasome subunits and triggers anti-multiple myeloma activity.

Amodio N, Stamato MA, Juli G, Morelli E, Fulciniti M, Manzoni M, Taiana E, Agnelli L, Cantafio MEG, Romeo E, Raimondi L, Caracciolo D, Zuccalà V, Rossi M, Neri A, Munshi NC, Tagliaferri P, Tassone P.

Leukemia. 2018 Sep;32(9):1948-1957. doi: 10.1038/s41375-018-0067-3. Epub 2018 Feb 22.

7.

Long Non-Coding RNAs in Multiple Myeloma.

Nobili L, Ronchetti D, Agnelli L, Taiana E, Vinci C, Neri A.

Genes (Basel). 2018 Feb 1;9(2). pii: E69. doi: 10.3390/genes9020069. Review.

8.

Long non-coding RNAs in B-cell malignancies: a comprehensive overview.

Nobili L, Ronchetti D, Taiana E, Neri A.

Oncotarget. 2017 Apr 20;8(36):60605-60623. doi: 10.18632/oncotarget.17303. eCollection 2017 Sep 1. Review.

9.

Inactivation of CK1α in multiple myeloma empowers drug cytotoxicity by affecting AKT and β-catenin survival signaling pathways.

Manni S, Carrino M, Manzoni M, Gianesin K, Nunes SC, Costacurta M, Tubi LQ, Macaccaro P, Taiana E, Cabrelle A, Barilà G, Martines A, Zambello R, Bonaldi L, Trentin L, Neri A, Semenzato G, Piazza F.

Oncotarget. 2017 Feb 28;8(9):14604-14619. doi: 10.18632/oncotarget.14654.

10.

lncRNA profiling in early-stage chronic lymphocytic leukemia identifies transcriptional fingerprints with relevance in clinical outcome.

Ronchetti D, Manzoni M, Agnelli L, Vinci C, Fabris S, Cutrona G, Matis S, Colombo M, Galletti S, Taiana E, Recchia AG, Bossio S, Gentile M, Musolino C, Di Raimondo F, Grilli A, Bicciato S, Cortelezzi A, Tassone P, Morabito F, Ferrarini M, Neri A.

Blood Cancer J. 2016 Sep 9;6(9):e468. doi: 10.1038/bcj.2016.77.

11.

Distinct lncRNA transcriptional fingerprints characterize progressive stages of multiple myeloma.

Ronchetti D, Agnelli L, Taiana E, Galletti S, Manzoni M, Todoerti K, Musto P, Strozzi F, Neri A.

Oncotarget. 2016 Mar 22;7(12):14814-30. doi: 10.18632/oncotarget.7442.

12.

Disentangling the microRNA regulatory milieu in multiple myeloma: integrative genomics analysis outlines mixed miRNA-TF circuits and pathway-derived networks modulated in t(4;14) patients.

Calura E, Bisognin A, Manzoni M, Todoerti K, Taiana E, Sales G, Morgan GJ, Tonon G, Amodio N, Tassone P, Neri A, Agnelli L, Romualdi C, Bortoluzzi S.

Oncotarget. 2016 Jan 19;7(3):2367-78. doi: 10.18632/oncotarget.6151.

13.

Notch signaling deregulation in multiple myeloma: A rational molecular target.

Colombo M, Galletti S, Garavelli S, Platonova N, Paoli A, Basile A, Taiana E, Neri A, Chiaramonte R.

Oncotarget. 2015 Sep 29;6(29):26826-40. doi: 10.18632/oncotarget.5025. Review.

14.

The BH3-mimetic obatoclax reduces HIF-1α levels and HIF-1 transcriptional activity and sensitizes hypoxic colon adenocarcinoma cells to 5-fluorouracil.

Gariboldi MB, Taiana E, Bonzi MC, Craparotta I, Giovannardi S, Mancini M, Monti E.

Cancer Lett. 2015 Aug 10;364(2):156-64. doi: 10.1016/j.canlet.2015.05.008. Epub 2015 May 12.

PMID:
25979228
15.

Co-targeting the IGF system and HIF-1 inhibits migration and invasion by (triple-negative) breast cancer cells.

Mancini M, Gariboldi MB, Taiana E, Bonzi MC, Craparotta I, Pagin M, Monti E.

Br J Cancer. 2014 Jun 10;110(12):2865-73. doi: 10.1038/bjc.2014.269. Epub 2014 May 22.

Supplemental Content

Loading ...
Support Center